Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus KEYTRUDA in the neoadjuvant setting for patients with resectable soft tissue sarcoma, STS. The Phase II trial conducted by the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP: